Ipsen v. Conjupro Biotherapeutics: ONIVYDE® Patent Case Consolidated in NJ
Ipsen asserted Orange Book-listed patent US12364691B2 covering its ONIVYDE® irinotecan liposome injection against Conjupro Biotherapeutics and CSPC affiliates. Filed July 22, 2025, the case was ordered consolidated with two earlier related actions within 45 days — consolidating all discovery, case management, and trial into a single New Jersey proceeding.
ONIVYDE® Orange Book Patent Dispute Consolidated in New Jersey
Ipsen Biopharmaceuticals, Inc. and Ipsen Biopharm Ltd. filed Civil Action No. 1:25-cv-13647 on July 22, 2025 in the New Jersey District Court, asserting infringement of US12364691B2 — an Orange Book-listed patent for ONIVYDE® (irinotecan liposome injection) — against Conjupro Biotherapeutics, Inc. and affiliated CSPC entities. This action was the third in a series of related Hatch-Waxman-style proceedings Ipsen has brought against the same defendant group in the same judicial district.
The case closed as a standalone docket after just 45 days, not through dismissal or settlement, but through court-ordered consolidation. On August 21, 2025, the Court ordered Civil Action No. 25-13647 consolidated with the lead action, Civil Action No. 24-4991, for all purposes including discovery, case management, and trial. A subsequent September 3, 2025 conference addressed scheduling specifics, including narrowing of patent claims and prior art. The formal consolidation order issued September 5, 2025.
The rapid consolidation — under 45 days — suggests the Court moved decisively to manage what had become a multi-filing dispute across three civil actions. The public record does not reveal the underlying claim scope at issue in this specific filing relative to the earlier actions, nor which specific claims of US12364691B2 will survive narrowing. The substantive merits of Ipsen’s infringement allegations and Conjupro/CSPC’s defenses remain to be litigated in the consolidated proceeding.
Filing to Case Consolidated in 45 days
45 days from filing to consolidation order — faster than typical district court motion timelines
Case transferred into consolidated action: what this means for both parties
Consolidation is a procedural merger, not a dismissal
When a court consolidates cases under Federal Rule of Civil Procedure 42(a), it merges related actions into a single proceeding to avoid duplicative discovery and inconsistent rulings. Case 25-cv-13647 is terminated as a standalone docket but survives substantively — all claims and defenses continue under the lead action, Civil Action No. 24-4991. No rights are waived; no merits have been decided.
Rule 42(a) consolidationIpsen retains all enforcement leverage in one unified proceeding
Consolidation typically benefits a plaintiff managing multiple related filings — it streamlines Ipsen’s enforcement strategy against Conjupro/CSPC by combining all Orange Book patent claims into one case. Ipsen avoids the risk of inconsistent rulings across parallel actions while preserving its ability to assert the full scope of US12364691B2 and any co-asserted patents. The earlier lead action’s discovery schedule governs going forward.
Enforcement continuesConjupro/CSPC faces a single, coordinated litigation front
For Conjupro Biotherapeutics and the CSPC entities, consolidation concentrates the litigation risk into one proceeding. The Court’s instruction to narrow patent claims and prior art references suggests early case management pressure. Defendants must coordinate their invalidity and non-infringement positions across what were three separate actions, though they also benefit from a single, unified discovery process rather than parallel obligations.
Unified defence requiredLiposomal oncology IP: multi-filing strategy signals broad enforcement intent
Ipsen’s decision to file a third related action in 2025 — after two 2024 filings — is consistent with Orange Book patent listing enforcement patterns where innovators sequentially assert newly issued patents. For biosimilar and generic entrants in the liposomal drug delivery space, this case signals that ONIVYDE®-adjacent product development carries ongoing litigation exposure. The consolidated proceeding will set precedent on US12364691B2’s enforceability and claim scope.
Liposomal oncology IP riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Ipsen | Individual | Pharmaceutical innovator — holder of US12364691B2, Orange Book patent for ONIVYDE®Search in Eureka ↗ |
| Defendant | CONJUPRO BIOTHERAPEUTICS, INC. | Company | Conjupro Biotherapeutics, Inc. and CSPC affiliates — pharmaceutical challengersSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for IpsenSearch in Eureka ↗ |
| Plaintiff counsel | Charles Michael Lizza | Attorney | Counsel for IpsenSearch in Eureka ↗ |
| Plaintiff counsel | Sarah Ann Sullvian | Attorney | Counsel for IpsenSearch in Eureka ↗ |
| Plaintiff law firm | Saul Ewing LLP | Law Firm | Representing IpsenSearch in Eureka ↗ |
| Defendant counsel | Paul W. Kalish | Attorney | Counsel for CONJUPRO BIOTHERAPEUTICS, INC.Search in Eureka ↗ |
| Defendant law firm | Fox Rothschild LLP | Law Firm | Representing CONJUPRO BIOTHERAPEUTICS, INC.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is procedural in nature and carries no merits determination. The Court’s language — consolidating ‘for all purposes, including discovery, case management, and trial’ — indicates a full merger of the proceedings, not a limited administrative alignment. The direction to narrow patent claims and prior art references before a subsequent conference suggests the Court intends to actively manage claim scope from an early stage, which may constrain both Ipsen’s assertion breadth and Conjupro/CSPC’s invalidity positions in the consolidated action.
US12364691B2 — Irinotecan Liposome Injection (ONIVYDE®)
US12364691B2, filed under application number US17/824421, is listed in the FDA Orange Book for ONIVYDE® — irinotecan liposome injection, an oncology product used in the treatment of certain pancreatic cancers. Orange Book listing confers statutory significance under Hatch-Waxman: any ANDA or 505(b)(2) filer referencing ONIVYDE® must certify against this patent, triggering potential automatic 30-month stays. The patent covers liposomal drug delivery technology applied to irinotecan, a topoisomerase I inhibitor.
US12364691B2’s Orange Book status makes it a front-line exclusivity asset for Ipsen in the ONIVYDE® franchise. Its assertion across three consecutive civil actions between 2024 and 2025 — alongside earlier-issued Orange Book patents — indicates Ipsen views this patent as central to defending market position against Conjupro/CSPC’s pipeline. For competitors developing liposomal irinotecan formulations, the claim scope as ultimately construed will define the boundaries of a viable design-around or freedom-to-operate position.
Should you run an FTO against US12364691B2 for liposomal irinotecan products?
Any company developing an irinotecan liposome injection product — whether as an ANDA filer, 505(b)(2) applicant, or innovator with a competing liposomal oncology formulation — faces direct exposure to US12364691B2 given its active Orange Book listing. The claim scope, as narrowed through the consolidated New Jersey proceedings, will determine whether alternative formulations or manufacturing approaches can achieve clearance. R&D and regulatory teams should not wait for the litigation outcome to begin FTO analysis.
PatSnap Eureka’s FTO Search Agent enables IP teams to map the claim boundaries of US12364691B2 against their specific formulation approaches, identify prior art that may inform invalidity arguments, and monitor prosecution history for file wrapper estoppel signals. As claim narrowing proceeds in the consolidated action, Eureka’s real-time monitoring ensures your FTO position reflects the most current claim scope — critical in fast-moving Hatch-Waxman litigation environments.
Run a freedom-to-operate analysis on US12364691B2 to assess your product’s exposure
Run FTO in Eureka →Similar Orange Book patent cases: liposomal drug delivery litigation in NJ
Cases involving Orange Book patent enforcement for liposomal oncology formulations in New Jersey District Court, with comparable Hatch-Waxman procedural profiles.
What this case signals for the liposomal drug delivery IP landscape
Ipsen’s three-action enforcement campaign against Conjupro/CSPC reflects a broader trend of layered Orange Book patent enforcement in oncology drug delivery.
Sequential Orange Book filings are a deliberate enforcement architecture
Ipsen filed three separate civil actions against the same defendants between April 2024 and July 2025, each tied to Orange Book patents for ONIVYDE®. This pattern — filing new cases as additional patents issue — is a recognised strategy to extend litigation timelines and maintain market exclusivity pressure on generic or biosimilar challengers in liposomal oncology.
Court-ordered claim narrowing signals active case management pressure
The September 3, 2025 conference specifically addressed narrowing patent claims and prior art references. This is consistent with New Jersey District Court’s proactive management of complex Hatch-Waxman proceedings and suggests both parties face near-term pressure to crystallise their positions on claim scope and invalidity arguments earlier than typical schedules might allow.
Ipsen v CONJUPRO — key questions answered
Case 1:25-cv-13647 was consolidated into lead action Civil Action No. 24-4991 on September 5, 2025. Ipsen filed the case on July 22, 2025 asserting Orange Book patent US12364691B2 for ONIVYDE® against Conjupro Biotherapeutics and CSPC affiliates. The standalone docket closed after 45 days when the New Jersey District Court ordered full consolidation including discovery, case management, and trial.
US12364691B2 (application US17/824421) is a patent covering irinotecan liposome injection technology and is listed in the FDA Orange Book for Ipsen’s ONIVYDE® product. Orange Book listing means generic or 505(b)(2) applicants referencing ONIVYDE® must certify against this patent, potentially triggering a 30-month automatic stay of FDA approval under Hatch-Waxman — making it a key exclusivity asset for Ipsen.
The defendants named across Ipsen’s consolidated ONIVYDE® proceedings are Conjupro Biotherapeutics, Inc., CSPC Pharmaceutical Group Limited, and CSPC Ouyi Pharmaceutical Co., Ltd. — collectively referred to in court documents as ‘Conjupro/CSPC’. CSPC entities are significant Chinese pharmaceutical manufacturers, suggesting the dispute has cross-border manufacturing and supply chain dimensions.
Consolidation under Rule 42(a) merges all three Ipsen v. Conjupro/CSPC actions — Nos. 24-4991, 24-8723, and 25-13647 — into a single proceeding for all purposes. No claims are dismissed; no merits are decided. Litigation continues under the lead docket (24-4991) with one unified discovery process and trial. The Court has also directed narrowing of patent claims and prior art, indicating active early case management.
ONIVYDE® (irinotecan liposome injection) is an Ipsen oncology product approved by the FDA for the treatment of certain pancreatic cancers, including metastatic pancreatic adenocarcinoma. It uses liposomal encapsulation to deliver irinotecan — a topoisomerase I inhibitor — and is covered by multiple Orange Book-listed patents that Ipsen has actively enforced through litigation in the New Jersey District Court.
PatSnap Eureka searches patents and litigation data to answer instantly.